Download PDF
Semin intervent Radiol 2024; 41(04): 404-412
DOI: 10.1055/s-0044-1791538
Review Article

The Role of Medical Management in Vascular Anomalies

Michael H. White
,
C. Matthew Hawkins
3   Children's Healthcare of Atlanta, Vascular Anomalies Clinic, Atlanta, Georgia
4   Division of Pediatric Radiology, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Historically, the care for patients with vascular anomalies has been challenging due to the complex nature and diversity of these anomalies with a wide array of symptomatology. In the recent past, most therapies for vascular anomalies focused on surgical, procedural, and supportive care measures to treat local symptoms, but many patients still experienced significant disease with excess morbidity and mortality. Today, the pharmacotherapeutic options available for treating vascular anomalies have greatly expanded due to the increased understanding of the genetic and molecular pathways causing these anomalies, with the subsequent development of more targeted pharmacotherapies. In addition to the growth in targeted medications available to treat patients with vascular anomalies, there has been an improved understanding of the hematologic abnormalities related to these diseases and how to manage them. While interventional radiologists do not typically primarily manage systemic medications to treat vascular anomalies, a baseline understanding of the medical management of these diseases is essential to ensuring that a contemporary, multidisciplinary, multimodal approach to treatment is pursued when appropriate. Ultimately, patients are now benefitting from having multiple modalities of treatments available to them and are experiencing improved quality of life and less morbidity.

Keywords

alpelisib - sirolimus - vascular anomalies - hematology - interventional radiology


Publication History

Article published online:
07 November 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ricci KW. Advances in the medical management of vascular anomalies. Semin Intervent Radiol 2017; 34 (03) 239-249
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Rochon PJ. Importance of multidisciplinary approach to vascular malformation management. Semin Intervent Radiol 2017; 34 (03) 301-302
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Mansur A, Radovanovic I. Vascular malformations: an overview of their molecular pathways, detection of mutational profiles and subsequent targets for drug therapy. Front Neurol 2023; 14: 1099328
    CrossrefPubMedGoogle Scholar
  • 4 Al-Olabi L, Polubothu S, Dowsett K. et al. Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy. J Clin Invest 2018; 128 (11) 5185
    CrossrefPubMedGoogle Scholar
  • 5 Borst AJ, Hammill AM, Crary SE, McLean TW, Felton T, Blatt J. Barriers to genetic testing in vascular malformations. JAMA Netw Open 2023; 6 (05) e2314829
    CrossrefPubMedGoogle Scholar
  • 6 diMonda J, Al-Jaberi R, Abunimer A. et al. Disparities in the molecular diagnosis of vascular malformations in clinical practice: a comparative analysis of specimen types and depth of coverage. Abstract 336. ISSVA 2024 Annual Meeting. Accessed August 26, 2024 at: https://www.issva.org/UserFiles/file/ISSVAWC24ProgramBook.pdf
    PubMedGoogle Scholar
  • 7 Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010; 40 (02) 310-322
    CrossrefPubMedGoogle Scholar
  • 8 Hammill AM, Wentzel M, Gupta A. et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57 (06) 1018-1024
    CrossrefPubMedGoogle Scholar
  • 9 Adams DM, Trenor III CC, Hammill AM. et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137 (02) e20153257
    CrossrefPubMedGoogle Scholar
  • 10 Wiegand S, Dietz A, Wichmann G. Efficacy of sirolimus in children with lymphatic malformations of the head and neck. Eur Arch Otorhinolaryngol 2022; 279 (08) 3801-3810
    CrossrefPubMedGoogle Scholar
  • 11 Soblet J, Limaye N, Uebelhoer M, Boon LM, Vikkula M. Variable somatic TIE2 mutations in half of sporadic venous malformations. Mol Syndromol 2013; 4 (04) 179-183
    CrossrefPubMedGoogle Scholar
  • 12 Limaye N, Wouters V, Uebelhoer M. et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009; 41 (01) 118-124
    CrossrefPubMedGoogle Scholar
  • 13 Nätynki M, Kangas J, Miinalainen I. et al. Common and specific effects of TIE2 mutations causing venous malformations. Hum Mol Genet 2015; 24 (22) 6374-6389
    CrossrefPubMedGoogle Scholar
  • 14 Soblet J, Kangas J, Nätynki M. et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J Invest Dermatol 2017; 137 (01) 207-216
    CrossrefPubMedGoogle Scholar
  • 15 Limaye N, Kangas J, Mendola A. et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet 2015; 97 (06) 914-921
    CrossrefPubMedGoogle Scholar
  • 16 Ebrahimi-Fakhari D, Stires G, Hahn E, Krueger D, Franz DN. Prenatal sirolimus treatment for rhabdomyomas in tuberous sclerosis. Pediatr Neurol 2021; 125: 26-31
    CrossrefPubMedGoogle Scholar
  • 17 Livingston J, Alrowaily N, John P. et al. Fetal therapy using rapamycin for a rapidly enlarging, obstructive, cervical lymphatic malformation: a case report. Prenat Diagn 2021; 41 (07) 884-887
    CrossrefPubMedGoogle Scholar
  • 18 Uno T, Ito S, Nakazawa A, Miyazaki O, Mori T, Terashima K. Successful treatment of Kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer 2015; 62 (03) 536-538
    CrossrefPubMedGoogle Scholar
  • 19 Le Sage S, David M, Dubois J. et al. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: a case series. Pediatr Dermatol 2018; 35 (04) 472-477
    CrossrefPubMedGoogle Scholar
  • 20 Teng JMC, Hammill A, Martini J, Treat J. Sirolimus in the treatment of microcystic lymphatic malformations: a systematic review. Lymphat Res Biol 2023; 21 (02) 101-110
    CrossrefPubMedGoogle Scholar
  • 21 André F, Ciruelos E, Rubovszky G. et al; SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019; 380 (20) 1929-1940
    CrossrefPubMedGoogle Scholar
  • 22 Canaud G, Lopez Gutierrez JC, Irvine AD. et al. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med 2023; 25 (12) 100969
    CrossrefPubMedGoogle Scholar
  • 23 ISSVA Classification of Vascular Anomalies ©2018 International Society for the Study of Vascular Anomalies. 2018 . Available at: issva.org/classification . Accessed June 2024
    PubMedGoogle Scholar
  • 24 Luks VL, Kamitaki N, Vivero MP. et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 2015; 166 (04) 1048-54.e1 , 5
    CrossrefPubMedGoogle Scholar
  • 25 Wang H, Xie C, Lin W, Wang P, Yang W, Guo Z. Fibro-adipose vascular anomaly (FAVA) - diagnosis, staging and management. Orphanet J Rare Dis 2023; 18 (01) 347
    CrossrefPubMedGoogle Scholar
  • 26 Adams DM, Ricci KW. Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options. Hematol Oncol Clin North Am 2019; 33 (03) 455-470
    CrossrefPubMedGoogle Scholar
  • 27 Borst AJ, Nakano TA, Blei F, Adams DM, Duis J. A primer on a comprehensive genetic approach to vascular anomalies. Front Pediatr 2020; 8: 579591
    CrossrefPubMedGoogle Scholar
  • 28 Cramer SL, Wei S, Merrow AC, Pressey JG. Gorham-Stout disease successfully treated with sirolimus and zoledronic acid therapy. J Pediatr Hematol Oncol 2016; 38 (03) e129-e132
    CrossrefPubMedGoogle Scholar
  • 29 Bauditz J. Effective treatment of gastrointestinal bleeding with thalidomide -- chances and limitations. World J Gastroenterol 2016; 22 (11) 3158-3164
    CrossrefPubMedGoogle Scholar
  • 30 Ge ZZ, Chen HM, Gao YJ. et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 141 (05) 1629-37.e1 , 4
    CrossrefPubMedGoogle Scholar
  • 31 Ricci KW, Brandão LR. Coagulation issues in vascular anomalies. Semin Pediatr Surg 2020; 29 (05) 150966
    CrossrefPubMedGoogle Scholar
  • 32 Zhuo KY, Russell S, Wargon O, Adams S. Localised intravascular coagulation complicating venous malformations in children: associations and therapeutic options. J Paediatr Child Health 2017; 53 (08) 737-741
    CrossrefPubMedGoogle Scholar
  • 33 Wille M. Coagulation disorders: typical coagulation abnormalities. Compendium Vasc Anomalies. 2021. Wohlgemuth, WA. Typical coagulation anomalies. Image © Müller-Wille. Updated February 24, 2021. In: Compendium Vascular Anomalies. Available at: https://www.compva.com/science/coagulation-disorders/typical-coagulation-anomalies . Accessed September 23, 2024
  • 34 Dompmartin A, Acher A, Thibon P. et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 2008; 144 (07) 873-877
    CrossrefPubMedGoogle Scholar
  • 35 Lagneaux E, Boon LM, Revencu N, Vikkula M, Hermans C. Direct oral anticoagulants and venous malformations: literature review and retrospective study of 29 patients. Res Pract Thromb Haemost 2024; 8 (03) 102400
    CrossrefPubMedGoogle Scholar
  • 36 Nguyen JT, Koerper MA, Hess CP. et al. Aspirin therapy in venous malformation: a retrospective cohort study of benefits, side effects, and patient experiences. Pediatr Dermatol 2014; 31 (05) 556-560
    CrossrefPubMedGoogle Scholar
  • 37 Lance EI, Sreenivasan AK, Zabel TA, Kossoff EH, Comi AM. Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. J Child Neurol 2013; 28 (02) 213-218
    CrossrefPubMedGoogle Scholar
  • 38 Smegal LF, Sebold AJ, Hammill AM. et al; National Institutes of Health Sponsor: Rare Disease Clinical Research Consortium (RDCRN) Brain Vascular Malformation Consortium (BVMC) SWS Investigator Group. Multicenter research data of epilepsy management in patients with Sturge-Weber syndrome. Pediatr Neurol 2021; 119: 3-10
    CrossrefPubMedGoogle Scholar
  • 39 Swerdlin RF, Briones MA, Gill AE, Hawkins CM. Coagulopathy and related complications following sclerotherapy of congenital venous malformations. Pediatr Blood Cancer 2022; 69 (05) e29610
    CrossrefPubMedGoogle Scholar
  • 40 Croteau SE, Liang MG, Kozakewich HP. et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162 (01) 142-147
    CrossrefPubMedGoogle Scholar
  • 41 O'Rafferty C, O'Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol 2015; 171 (01) 38-51
    CrossrefPubMedGoogle Scholar
  • 42 Kelly M. Kasabach-Merritt phenomenon. Pediatr Clin North Am 2010; 57 (05) 1085-1089
    CrossrefPubMedGoogle Scholar
  • 43 Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25 (02) 168-173
    CrossrefPubMedGoogle Scholar
  • 44 Chamli A, Aggarwal P, Jamil RT. et al. Hemangioma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538232/. Accessed September 23, 2024
    PubMed
  • 45 Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 2013; 131 (06) e1739-e1747
    CrossrefPubMedGoogle Scholar
  • 46 Khan M, Boyce A, Prieto-Merino D, Svensson Å, Wedgeworth E, Flohr C. The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol 2017; 97 (10) 1167-1171
    CrossrefPubMedGoogle Scholar
  • 47 Leung AKC, Lam JM, Leong KF, Hon KL. Infantile hemangioma: an updated review. Curr Pediatr Rev 2021; 17 (01) 55-69
    PubMedGoogle Scholar
  • 48 Malik MA, Menon P, Rao KL, Samujh R. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg 2013; 48 (12) 2453-2459
    CrossrefPubMedGoogle Scholar
  • 49 Bauman NM, McCarter RJ, Guzzetta PC. et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2014; 140 (04) 323-330
    CrossrefPubMedGoogle Scholar
  • 50 Patel NJ, Bauman NM. How should propranolol be initiated for infantile hemangiomas: inpatient versus outpatient?. Laryngoscope 2014; 124 (06) 1279-1281
    CrossrefPubMedGoogle Scholar
  • 51 Tubbs RS, Wellons III JC, Iskandar BJ, Oakes WJ. Isolated flat capillary midline lumbosacral hemangiomas as indicators of occult spinal dysraphism. J Neurosurg 2004; 100 (2, Suppl Pediatrics): 86-89
    PubMedGoogle Scholar
  • 52 Horii KA, Drolet BA, Frieden IJ. et al; Hemangioma Investigator Group. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol 2011; 28 (03) 245-253
    CrossrefPubMedGoogle Scholar